PSTV
PSTV
NASDAQ · Biotechnology

Plus Therapeutics Inc

$0.80
+0.12 (+17.65%)
Financial Highlights (FY 2026)
Revenue
50.13M
Net Income
-215,285,819
Gross Margin
—
Profit Margin
-429.4%
Rev Growth
-68.3%
D/E Ratio
0.19
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 60.8% 60.8%
Operating Margin -293.5% -264.1% 3.3% 3.5%
Profit Margin -429.4% -408.0% 3.0% 3.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 50.13M 157.90M 31.57M 32.41M
Gross Profit — — 19.20M 19.71M
Operating Income -147,119,107 -417,030,539 1.04M 1.13M
Net Income -215,285,819 -610,259,014 932.2K 975.1K
Gross Margin — — 60.8% 60.8%
Operating Margin -293.5% -264.1% 3.3% 3.5%
Profit Margin -429.4% -408.0% 3.0% 3.0%
Rev Growth -68.3% -68.3% +6.0% -3.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.10M 2.10M 17.01M 14.45M
Total Equity 11.21M 11.21M 23.46M 24.58M
D/E Ratio 0.19 0.19 0.73 0.59
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -142,840,479 -427,396,708 1.58M 1.77M
Free Cash Flow — — 483.5K 562.4K